AIM ImmunoTech is trading at $0.19, up 5.28%; no announcement has explicitly linked the move to a catalyst.

  • An October 5 release highlighted recent media coverage of Ampligen’s potential antiviral and biodefense applications, but did not report investor reaction or connect the coverage to the share-price rise.
  • The Nasdaq is up 0.69% and the S&P 500 is up 0.45%, offering potentially supportive context but not establishing the reason for AIM ImmunoTech’s move.